Clinical Trials Directory

Trials / Completed

CompletedNCT06166992

A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body

Investigation of Pharmacokinetics and Absolute Oral Bioavailability of BI 1291583 Administered as an Oral Dose With an Intravenous Microtracer Dose of [14C]-BI 1291583 in Healthy Male Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
14 (actual)
Sponsor
Boehringer Ingelheim · Industry
Sex
Male
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The main objective of this trial is to investigate the absolute bioavailability of BI 1291583 (test treatment T, not radio-labelled) compared with BI 1291583 (C-14) (reference treatment R).

Conditions

Interventions

TypeNameDescription
DRUGBI 1291583BI 1291583
DRUG[14C]-BI 1291583\[14C\]-BI 1291583

Timeline

Start date
2023-12-12
Primary completion
2024-02-07
Completion
2024-02-07
First posted
2023-12-12
Last updated
2025-08-13

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT06166992. Inclusion in this directory is not an endorsement.